However since the split is effective from January 1, earnings will include sales from proprietary drugs including Humira and AndroGel, which are expected to exhibit continued strong growth.
Some key background: In May 2003, Paddock filed an Abbreviated New Drug Application (ANDA) with FDA for approval of a generic version of AndroGel, as did another generic producer, Watson Pharmaceutical.